JP2006514111A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006514111A5 JP2006514111A5 JP2005508468A JP2005508468A JP2006514111A5 JP 2006514111 A5 JP2006514111 A5 JP 2006514111A5 JP 2005508468 A JP2005508468 A JP 2005508468A JP 2005508468 A JP2005508468 A JP 2005508468A JP 2006514111 A5 JP2006514111 A5 JP 2006514111A5
- Authority
- JP
- Japan
- Prior art keywords
- lactoferrin
- terminal
- oral preparation
- composition
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010063045 Lactoferrin Proteins 0.000 claims 49
- 102000010445 Lactoferrin Human genes 0.000 claims 49
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims 49
- 229940078795 lactoferrin Drugs 0.000 claims 49
- 235000021242 lactoferrin Nutrition 0.000 claims 49
- 238000002360 preparation method Methods 0.000 claims 23
- 239000000203 mixture Substances 0.000 claims 22
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 230000037430 deletion Effects 0.000 claims 6
- 238000012217 deletion Methods 0.000 claims 6
- 238000006467 substitution reaction Methods 0.000 claims 6
- 208000031729 Bacteremia Diseases 0.000 claims 4
- 206010040047 Sepsis Diseases 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 230000003014 reinforcing effect Effects 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 2
- 102000003810 Interleukin-18 Human genes 0.000 claims 2
- 108090000171 Interleukin-18 Proteins 0.000 claims 2
- 206010053159 Organ failure Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 101000798100 Bos taurus Lactotransferrin Proteins 0.000 claims 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 1
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 229940069428 antacid Drugs 0.000 claims 1
- 239000003159 antacid agent Substances 0.000 claims 1
- 230000001458 anti-acid effect Effects 0.000 claims 1
- 229940072440 bovine lactoferrin Drugs 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 230000016379 mucosal immune response Effects 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43139302P | 2002-12-06 | 2002-12-06 | |
| US60/431,393 | 2002-12-06 | ||
| US49832703P | 2003-08-27 | 2003-08-27 | |
| US60/498,327 | 2003-08-27 | ||
| PCT/US2003/038621 WO2004052281A2 (en) | 2002-12-06 | 2003-12-05 | Oral lactoferrin in the treatment of sepsis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010265361A Division JP2011068666A (ja) | 2002-12-06 | 2010-11-29 | 敗血症治療における経口用ラクトフェリン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006514111A JP2006514111A (ja) | 2006-04-27 |
| JP2006514111A5 true JP2006514111A5 (https=) | 2006-11-24 |
| JP4795021B2 JP4795021B2 (ja) | 2011-10-19 |
Family
ID=32511559
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005508468A Expired - Fee Related JP4795021B2 (ja) | 2002-12-06 | 2003-12-05 | 敗血症治療における経口用ラクトフェリン |
| JP2010265361A Pending JP2011068666A (ja) | 2002-12-06 | 2010-11-29 | 敗血症治療における経口用ラクトフェリン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010265361A Pending JP2011068666A (ja) | 2002-12-06 | 2010-11-29 | 敗血症治療における経口用ラクトフェリン |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20040152624A1 (https=) |
| EP (1) | EP1581243A4 (https=) |
| JP (2) | JP4795021B2 (https=) |
| AU (2) | AU2003298906A1 (https=) |
| CA (1) | CA2508912A1 (https=) |
| WO (1) | WO2004052281A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399570B1 (en) * | 1999-02-05 | 2002-06-04 | Agennix, Inc. | Antimicrobial/endotoxin neutralizing polypeptide |
| DE60335997D1 (de) | 2002-09-16 | 2011-03-24 | Agennix Inc | Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus |
| CA2508912A1 (en) * | 2002-12-06 | 2004-06-24 | Agennix Incorporated | Oral lactoferrin in the treatment of sepsis |
| AU2003296447A1 (en) | 2002-12-10 | 2004-06-30 | Agennix Incorporated | Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease |
| US8105615B2 (en) * | 2003-06-06 | 2012-01-31 | Agennix Incorporated | Lactoferrin as an adjuvant in cancer vaccines |
| WO2006047744A2 (en) * | 2004-10-26 | 2006-05-04 | Agennix Incorporated | Compositions of lactoferrin related peptides and uses thereof |
| ITMI20052351A1 (it) * | 2005-12-09 | 2007-06-10 | Microbo Srl | Nuovo uso farmaceutico delle transferrine e composizioni farmaceutiche derivate |
| WO2007109681A2 (en) * | 2006-03-20 | 2007-09-27 | Glanbia Nutritionals (Ireland) Limited | Compositions and methods for enhancing vasodilation |
| JP5087297B2 (ja) * | 2007-03-05 | 2012-12-05 | 森永乳業株式会社 | インターロイキン−１１産生促進剤 |
| ITRM20080163A1 (it) * | 2008-03-26 | 2009-09-27 | Maurizio Acri | Uso della lattoferrina per la prevenzione delle sepsi neonatali in neonati prematuri |
| US20130225477A1 (en) | 2010-02-25 | 2013-08-29 | Agennix Ag | Oral Lactoferrin in the Treatment of Severe Sepsis |
| CN101829075B (zh) * | 2010-04-27 | 2011-07-20 | 中国人民解放军第三军医大学第一附属医院 | 苦柯胺a和苦柯胺b的用途 |
| EP3017824B1 (en) * | 2013-04-09 | 2019-06-05 | The University of Tokyo | Inhibitor of extracellular trap formation in leukocytes |
| US20230149515A1 (en) * | 2020-04-29 | 2023-05-18 | The Regents Of The University Of Michigan | Inhibition of sars-cov-2 viral entry through oral administration of lactoferrin and uses thereof |
| WO2022145536A1 (ko) * | 2020-12-30 | 2022-07-07 | 경상대학교병원 | 급성 호흡 곤란 증후군 환자의 예후 예측을 위한 정보제공방법 |
| WO2023178060A1 (en) * | 2022-03-14 | 2023-09-21 | The Children's Mercy Hospital | Prophylaxis of neonatal escherichia coli sepsis |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2710997C3 (de) * | 1977-03-14 | 1980-08-14 | Dr. Karl Thomae Gmbh, 7950 Biberach | 4-Alkoxy carbonylamino-phenyläthanolamine, deren Herstellung und deren Verwendung als Arzneimittel |
| US4977137B1 (en) * | 1987-06-03 | 1994-06-28 | Baylor College Medicine | Lactoferrin as a dietary ingredient promoting the growth of the gastrointestinal tract |
| US5457093A (en) * | 1987-09-18 | 1995-10-10 | Ethicon, Inc. | Gel formulations containing growth factors |
| US5849881A (en) * | 1989-05-05 | 1998-12-15 | Baylor College Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms |
| IL94183A (en) * | 1989-05-05 | 2003-09-17 | Baylor College Medicine | cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE |
| US5571697A (en) * | 1989-05-05 | 1996-11-05 | Baylor College Of Medicine Texas Medical Center | Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus |
| US5766939A (en) * | 1989-05-05 | 1998-06-16 | Baylor College Of Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms |
| US6100054A (en) * | 1989-05-05 | 2000-08-08 | Baylor College Of Medicine | Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms |
| US5571691A (en) * | 1989-05-05 | 1996-11-05 | Baylor College Of Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms |
| US5198419A (en) * | 1989-12-08 | 1993-03-30 | Immuno Japan Inc. | Formulated medicines for enhancing the efficacy of beta-lactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria |
| US6066469A (en) * | 1990-03-08 | 2000-05-23 | Ferro Dynamics, Inc. | Cloning, expression, and uses of human lactoferrin |
| US5240909B1 (en) * | 1990-03-14 | 1998-01-20 | Dietrich Nitsche | Use of lactoferrin for treatment of toxic effects of endotoxins |
| ATE148631T1 (de) * | 1990-11-13 | 1997-02-15 | Santen Pharmaceutical Co Ltd | Therapeutische agens bei hornhautverletzungen |
| US5564109A (en) * | 1991-09-13 | 1996-10-08 | Eastman Kodak Company | Remote user interface for prioritizing and selecting from a plurality of document production peripheral devices |
| EP0559425B1 (en) * | 1992-03-02 | 1999-01-07 | Immuno Japan Inc. | Use of proteins belonging to the transferrin/lactoferrin family for potentiating the immune system |
| JPH06145068A (ja) * | 1992-04-02 | 1994-05-24 | Imuno Japan:Kk | 生体防御能賦活剤・感染症治療剤・生体防御能賦活性食品 |
| ZA932568B (en) * | 1992-04-24 | 1993-11-12 | Baylor College Midecine A Non | Production of recombinant human lactoferrin |
| DK0624376T3 (da) * | 1993-05-13 | 2000-07-24 | American Cyanamid Co | Fremstilling og anvendelse af LOS-udtømte ydre membranproteiner af gram-negative cocci |
| JP3506274B2 (ja) * | 1994-09-01 | 2004-03-15 | 雪印乳業株式会社 | 新規ペプチドおよび免疫賦活剤 |
| JPH08165248A (ja) * | 1994-12-15 | 1996-06-25 | Nobuo Kuriiwa | エンドトキシンによる炎症の抑止剤 |
| US20020016289A1 (en) * | 1995-06-01 | 2002-02-07 | Orla M. Conneely | Methods for treatment and prevention of helicobacter pylori infection using lactoferrin |
| US6025326A (en) * | 1995-07-07 | 2000-02-15 | Intrabiotics Pharmaceuticals, Inc. | Compositions and methods for the prevention and treatment of oral mucositis |
| US5834424A (en) * | 1995-07-12 | 1998-11-10 | Gambit International Limited | Use of lactoferrin for therapy of acute of chronic infectious diseases by the intracellular gram-positive pathogens streptococcus pyogenes and staphylococcus aureus |
| US6111081A (en) * | 1996-05-31 | 2000-08-29 | Baylor College Of Medicine | Lactoferrin variants and uses thereof |
| US6333311B1 (en) * | 1997-02-03 | 2001-12-25 | Pharming | Useful properties of human lactoferrin and variants thereof |
| EP0979099B1 (en) * | 1997-04-10 | 2005-06-15 | Agennix, Inc. | Use of lactoferin in the treatment of allergen induced disorders |
| US5981830A (en) * | 1997-05-30 | 1999-11-09 | Schering Aktiengesellschaft | Knockout mice and their progeny with a disrupted hepsin gene |
| US6096731A (en) * | 1998-06-24 | 2000-08-01 | Institute For Drug Research, Inc. | Method for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation |
| US6399570B1 (en) * | 1999-02-05 | 2002-06-04 | Agennix, Inc. | Antimicrobial/endotoxin neutralizing polypeptide |
| US20030203839A1 (en) * | 1999-10-29 | 2003-10-30 | Kruzel Marian L. | Immune enhancing composition containing lactoferrin |
| US6613741B2 (en) * | 1999-10-29 | 2003-09-02 | Ferro Dynamics, Inc. | Method for treating aseptic SIRS in humans and other animals |
| AU782539B2 (en) * | 2000-01-14 | 2005-08-04 | Meiji Dairies Corporation | Antigen-specific IgE antibody production inhibitors |
| JP4672163B2 (ja) * | 2000-03-24 | 2011-04-20 | 明治乳業株式会社 | グラム陰性菌のリピドａに対する特異的抗体産生を誘導する組成物。 |
| CA2410567A1 (en) * | 2000-05-24 | 2001-11-29 | Eli Lilly And Company | Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states |
| JP4683740B2 (ja) * | 2001-02-15 | 2011-05-18 | 明治乳業株式会社 | 炎症に伴う症状の軽減剤 |
| US20030096736A1 (en) * | 2001-05-09 | 2003-05-22 | Kruzel Marian L. | Lactoferrin for age related disorders in humans |
| CN100467059C (zh) * | 2002-05-10 | 2009-03-11 | 阿根尼克斯有限公司 | 乳铁蛋白在治疗恶性肿瘤疾病中的用途 |
| US7238661B2 (en) * | 2002-05-24 | 2007-07-03 | Agennix, Inc. | Oral lactoferrin in the treatment of respiratory disorders |
| DE60335997D1 (de) * | 2002-09-16 | 2011-03-24 | Agennix Inc | Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus |
| AU2003291206A1 (en) * | 2002-12-04 | 2004-06-23 | Agennix Incorporated | Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease |
| CA2508912A1 (en) * | 2002-12-06 | 2004-06-24 | Agennix Incorporated | Oral lactoferrin in the treatment of sepsis |
| AU2003296447A1 (en) * | 2002-12-10 | 2004-06-30 | Agennix Incorporated | Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease |
| AU2003293500A1 (en) * | 2002-12-12 | 2004-07-09 | Agennix Incorporated | Lactoferrin in the reduction of pain |
| WO2004103285A2 (en) * | 2003-05-14 | 2004-12-02 | Agennix Incorporated | Lactoferrin in the treatment of diabetes mellitus |
| US8105615B2 (en) * | 2003-06-06 | 2012-01-31 | Agennix Incorporated | Lactoferrin as an adjuvant in cancer vaccines |
| WO2005018542A2 (en) * | 2003-07-10 | 2005-03-03 | Agennix Incorporated | Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects |
-
2003
- 2003-12-05 CA CA002508912A patent/CA2508912A1/en not_active Abandoned
- 2003-12-05 WO PCT/US2003/038621 patent/WO2004052281A2/en not_active Ceased
- 2003-12-05 EP EP03796665A patent/EP1581243A4/en not_active Withdrawn
- 2003-12-05 US US10/728,521 patent/US20040152624A1/en not_active Abandoned
- 2003-12-05 JP JP2005508468A patent/JP4795021B2/ja not_active Expired - Fee Related
- 2003-12-05 AU AU2003298906A patent/AU2003298906A1/en not_active Abandoned
-
2010
- 2010-01-19 AU AU2010200210A patent/AU2010200210A1/en not_active Abandoned
- 2010-02-08 US US12/702,216 patent/US20100210510A1/en not_active Abandoned
- 2010-11-29 JP JP2010265361A patent/JP2011068666A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006514111A5 (https=) | ||
| ES2358645T3 (es) | Composiciones de lactoferrina y métodos de tratamiento de la úlcera diabética. | |
| EP2479277A3 (en) | Compositions and methods of use for MGD-CSF in disease treatment | |
| CN102292346B (zh) | 肥胖的治疗 | |
| JP2006507270A5 (https=) | ||
| WO2005117967A3 (en) | Anti-il-9 antibody formulations and uses thereof | |
| ES2316567T3 (es) | Adeponectina para la regeneracion hepatica. | |
| HRP20171217T1 (hr) | Stabilni pripravak koji sadrži pthrp i njegova upotreba | |
| SE9800550D0 (sv) | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof | |
| JPH02502192A (ja) | 顆粒球コロニー刺激因子を用いる粘膜炎の予防及び治療法 | |
| EP1739178A3 (en) | Delivery of trefoil peptides | |
| AP2002002410A0 (en) | Hydrodynamically Balancing Oral Drug Delivery System | |
| EP0879245A1 (en) | Synthetic il-10 analogues | |
| JP2011068666A (ja) | 敗血症治療における経口用ラクトフェリン | |
| ES2640979T3 (es) | Formulaciones de células viables para administración oral | |
| KR101267967B1 (ko) | 면역 관련 질병을 예방 및 치료하기 위한 조성물 및 방법 | |
| JP2005508338A5 (https=) | ||
| WO2008020096A1 (es) | Composición farmacéutica con promotores de absorción | |
| ES2547379T3 (es) | Utilización de calcitonina para el tratamiento de la AR | |
| US12146005B2 (en) | Compositions and methods for treatment of fungal infections | |
| RU2295972C2 (ru) | Композиции на основе белков матрикса зубной эмали для модуляции иммунного ответа | |
| MacDonald et al. | Keratinocyte Growth Factor (KGF) in hematology and oncology | |
| JP2818834B2 (ja) | ＩＬ−１α安定化医薬製剤 | |
| ES2356371T3 (es) | Medicamentos terapéuticos para inducir tolerancia. | |
| Mizushima et al. | Oral administration of leflunomide (HWA486) results in prominent suppression of immunoglobulin E formation in a rat type 1 allergy model |